These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 8033091)

  • 21. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of green tea compounds on irinotecan metabolism.
    Mirkov S; Komoroski BJ; Ramírez J; Graber AY; Ratain MJ; Strom SC; Innocenti F
    Drug Metab Dispos; 2007 Feb; 35(2):228-33. PubMed ID: 17108060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
    Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
    Sasaki Y; Hakusui H; Mizuno S; Morita M; Miya T; Eguchi K; Shinkai T; Tamura T; Ohe Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):101-10. PubMed ID: 7737901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of irinotecan.
    Kuhn JG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
    Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
    Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonlinear pharmacokinetics of CPT-11 in rats.
    Kaneda N; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1721-5. PubMed ID: 2306726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
    Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
    Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma.
    Gornet JM; Lokiec F; Duclos-Vallee JC; Azoulay D; Goldwasser F
    Anticancer Res; 2001; 21(6A):4203-6. PubMed ID: 11911319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
    Charasson V; Haaz MC; Robert J
    Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
    Mallick P; Shah P; Gandhi A; Ghose R
    Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
    Rivory LP; Bowles MR; Robert J; Pond SM
    Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
    Tobin PJ; Beale P; Noney L; Liddell S; Rivory LP; Clarke S
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):309-16. PubMed ID: 16003560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
    Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
    Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes.
    Haaz MC; Rivory L; Jantet S; Ratanasavanh D; Robert J
    Pharmacol Toxicol; 1997 Feb; 80(2):91-6. PubMed ID: 9060040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.